28SEP11

Hepatocellular Carcinoma resulting from chronic Hepatitis B may result from the actions of viral-human RNA hybrids. A hybrid of the human LINE protein and viral X protein was shown to sequester miR-122 while causin abnormal hepatic cell division in mice by promoting the epithelial-mesenchymal transition [2015]

Specific miRNA detection, using methylene blue as an indicator [2015]

Reduction of miR-761 is involved in exercise-induced muscle mitochondrial biogenesis in a mechanism that involves peroxisome-proliferator activated receptor -gamma coactivator 1 (PGC-1a). Overexpression of miR-761 downregulated the p38 MAPK signalling pathway [2015]

miR-21, -155, 19a, 17-5p, and let-7 were profiled in samples of normal and malignant breast tissue. Low let-7 was linked to lymphatic invasion, downregulation of miR-21 reflected necrosis. Both are suggested as markers for breast cancer prognosis [2015]

Profile of miRNA in exercising versus sedentary rats recovering from heart failure. Many more miRNAs were disregulated in the exercise group with miR-598, -429, -224, -425, and -221 particularly increased providing a potential role in cardioprotection. [2015].

Comparism of normalisation strategies in miRNA quantification using a reference small RNA [2015]

25SEP15.

Profile of cancerous oesophogeal tissue, expression data obtained from the Cancer Genome Atlas database and annotated with GO and KEGG databases. TargetScan and Miranda were used to relate miRNA activity and gene expression while TRANSFAC was used to identify promoter sites. A network of TF->>miRNA->>gene transcripts was established with CPBP, NFAT-1, and miR-30c-5p at the centre[2015].

patent:METHODS AND COMPOSITIONS RELATING TO CARCINOMA STEM CELLS

[cta]

conference: AACR

teleconference
[cta]

patent: (WO/2009/091982) MIR-122 AGONIST

Synthetic oligo-nts backbone-modified or liganded to increase stability, with tailored miR sequences.
[cta]

patent: (WO/2009/091659) GENERATION OF TUMOR-FREE EMBRYONIC STEM-LIKE PLURIPOTENT CELLS USING INDUCIBLE RECOMBINANT RNA AGENTS

[cta]

patent: (WO/2009/091904) MICRORNA BASED METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER

[cta]